Downstream processing of monoclonal antibodies--application of platform approaches.

This paper describes the key elements of a flexible, generic downstream process platform for mAbs that has been adopted at Amgen and consists of a well-defined sequence of unit operations with most operating parameters being pre-defined and a small subset of parameters requiring development effort.